Blocking cardiac growth in hypertrophic cardiomyopathy induces cardiac dysfunction and decreased survival only in males

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 292, Issue 2, 2007, Pages

  Luckey, Stephen W ^a   Mansoori, Jason ^a   Fair, Kelly ^a   Antos, Christopher L ^b   Olson, Eric N ^c   Leinwand, Leslie A ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b MAX PLANCK INSTITUTE FOR DEVELOPMENTAL BIOLOGY   (Germany)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cardiac hypertrophy; Glycogen synthase kinase 3 ; Myosin heavy chain

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ATRIAL NATRIURETIC FACTOR; CASEIN; SOYBEAN PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; ENZYME ACTIVATION; HEART DISEASE; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOPLASMIC RETICULUM; SEX DIFFERENCE; SEX RATIO; SIGNAL TRANSDUCTION; SUDDEN DEATH; SURVIVAL;

ACTINS; ANIMALS; ATRIAL NATRIURETIC FACTOR; CALCIUM-BINDING PROTEINS; CARDIOMYOPATHY, HYPERTROPHIC; CROSSES, GENETIC; DIETARY PROTEINS; DISEASE MODELS, ANIMAL; FEMALE; FIBROSIS; GLYCOGEN SYNTHASE KINASE 3; HEART VENTRICLES; KAPLAN-MEIERS ESTIMATE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; MYOCARDIAL CONTRACTION; MYOSIN HEAVY CHAINS; PHOSPHORYLATION; RNA, MESSENGER; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SEX FACTORS; TIME FACTORS; VENTRICULAR REMODELING;

EID: 33846997582     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00615.2006     Document Type: Article

References (40)

1. Antos CL, McKinsey TA, Frey N, Kutschke W, McAnally J, Shelton JM, Richardson JA, Hill JA, Olson EN. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 99: 907-912, 2002.
2. Badorff C, Ruetten H, Mueller S, Stahmer M, Gehring D, Jung F, Ihling C, Zeiher AM, Dimmeler S. Fas receptor signaling inhibits glycogen synthase kinase 3 beta and induces cardiac hypertrophy following pressure overload. J Clin Invest 109: 373-381, 2002.
3. Brancaccio M, Fratta L, Notte A, Hirsch E, Poulet R, Guazzone S, De Acetis M, Vecchione C, Marino G, Altruda F, Silengo L, Tarone G, Lembo G. Melusin, a muscle-specific integrin β1-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload. Nat Med 9: 68-75, 2003.
4. Dash R, Schmidt AG, Pathak A, Gerst MJ, Biniakiewicz D, Kadambi VJ, Hoit BD, Abraham WT, Kranias EG. Differential regulation of p38 mitogen-activated protein kinase mediates gender-dependent catecholamine-induced hypertrophy. Cardiovasc Res 57: 704-714, 2003.
5. Du XJ. Gender modulates cardiac phenotype development in genetically modified mice. Cardiovasc Res 63: 510-519, 2004.
6. Esposito G, Rapacciuolo A, Naga Prasad SV, Takaoka H, Thomas SA, Koch WJ, Rockman HA. Genetic alterations that inhibit in vivo pressureoverload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 105: 85-92, 2002.
7. Freeman K, Colon-Rivera C, Olsson MC, Moore RL, Weinberger HD, Grupp IL, Vikstrom KL, Iaccarino G, Koch WJ, Leinwand LA. Progression from hypertrophic to dilated cardiomyopathy in mice that express a mutant myosin transgene. Am J Physiol Heart Circ Physiol 280: H151-H159, 2001.
8. Freeman K, Lerman I, Kranias EG, Bohlmeyer T, Bristow MR, Lefkowitz RJ, Iaccarino G, Koch WJ, Leinwand LA. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest 107: 967-974, 2001.
9. Gao XM, Agrotis A, Autelitano DJ, Percy E, Woodcock EA, Jennings GL, Dart AM, Du XJ. Sex hormones and cardiomyopathic phenotype induced by cardiac β2-adrenergic receptor overexpression. Endocrinology 144: 4097-4105, 2003.
10. Geisterfer-Lowrance AAT, Christe M, Conner DA, Ingwall JS, Schoen FJ, Seidman CE, Seidman JG. A mouse model of familial hypertrophic cardiomyopathy. Science 272: 731-734, 1996.
11. Gradman AH, Alfayoumi F. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease. Prog Cardiovasc Dis 48: 326-341, 2006.
12. Haghighi K, Schmidt AG, Hoit BD, Brittsan AG, Yatani A, Lester JW, Zhai J, Kimura Y, Dorn GW, 2nd MacLennan DH, Kranias EG. Superinhibition of sarcoplasmic reticulum function by phospholamban induces cardiac contractile failure. J Biol Chem 276: 24145-24152, 2001.
13. Haq S, Choukroun G, Kang ZB, Ranu H, Matsui T, Rosenzweig A, Molkentin JD, Alessandrini A, Woodgett J, Hajjar R, Michael A, Force T. Glycogen synthase kinase-3β is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol 151: 117-130, 2000.
14. Hardt SE, Sadoshima J. Negative regulators of cardiac hypertrophy. Cardiovasc Res 63: 500-509, 2004.
15. Izumo S, Nadal-Ginard B, Mahdavi V. Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload. Proc Natl Acad Sci USA 85: 339-343, 1988.
16. Kadokami T, McTiernan CF, Kubota T, Frye CS, Feldman AM. Sex-related survival differences in murine cardiomyopathy are associated with differences in TNF-receptor expression. J Clin Invest 106: 589-597, 2000.
17. Konhilas JP, Maass AH, Luckey SW, Ikeda K, Stauffer BL, Olson EN, Leinwand LA. Sex modifies exercise and cardiac adaptation in the mouse. Am J Physiol Heart Circ Physiol 287: H2768-H2776, 2004.
18. Leinwand LA. Sex is a potent modifier of the cardiovascular system. J Clin Invest 112: 302-307, 2003.
19. MacLennan DH, Kranias EG. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol 4: 566-577, 2003.
20. Marano G, Palazzesi S, Vergari A, Catalano L, Gaudi S, Testa C, Canese R, Carpinelli G, Podo F, Ferrari AU. Inhibition of left ventricular remodelling preserves chamber systolic function in pressure-overloaded mice. Pflügers Arch 446: 429-436, 2003.
21. Marian AJ, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol 33: 655-670, 2001.
22. Meguro T, Hong C, Asai K, Takagi G, McKinsey TA, Olson EN, Vatner SF. Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ Res 84: 735-740, 1999.
23. Michael A, Haq S, Chen X, Hsich E, Cui L, Walters B, Shao Z, Bhattacharya K, Kilter H, Huggins G, Andreucci M, Periasamy M, Solomon RN, Liao R, Patten R, Molkentin JD, Force T. Glycogen synthase kinase-3β regulates growth, calcium homeostasis, and diastolic function in the heart. J Biol Chem 279: 21383-21393, 2004.
24. Morisco C, Sadoshima J, Trimarco B, Arora R, Vatner DE, Vatner SF. Is treating cardiac hypertrophy salutary or detrimental: the two faces of Janus. Am J Physiol Heart Circ Physiol 284: H1043-H1047, 2003.
25. Oliver PM, Fox JE, Kim R, Rockman HA, Kim HS, Reddick RL, Pandey KN, Milgram SL, Smithies O, Maeda N. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci USA 94: 14730-14735, 1997.
26. Olsson MC, Palmer BM, Leinwand LA, Moore RL. Gender and aging in a transgenic mouse model of hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 280: H1136-H1144, 2001.
27. Ostman-Smith I. Reduction by oral propranolol treatment of left ventricular hypertrophy secondary to pressure-overload in the rat. Br J Pharmacol 116: 2703-2709, 1995.
28. Ostman-Smith I, Wettrell G, Riesenfeld T. A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose β-adrenoceptor antagonist treatment. J Am Coll Cardiol 34: 1813-1822, 1999.
29. Perlini S, Ferrero I, Palladini G, Tozzi R, Gatti C, Vezzoli M, Cesana F, Janetti MB, Clari F, Busca G, Mancia G, Ferrari AU. Survival benefits of different antiadrenergic interventions in pressure overload left ventricular hypertrophy/failure. Hypertension 48: 93-97, 2006.
30. Perlini S, Palladini G, Ferrero I, Tozzi R, Fallarini S, Facoetti A, Nano R, Clari F, Busca G, Fogari R, Ferrari AU. Sympathectomy or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload hypertrophy. Hypertension 46: 1213-1218, 2005.
31. Poliac LC, Barron ME, Maron BJ. Hypertrophic cardiomyopathy. Anesthesiology 104: 183-192, 2006.
32. Robbins J. Remodeling the cardiac sarcomere using transgenesis. Annu Rev Physiol 62: 261-287, 2000.
33. Rogers JH, Tamirisa P, Kovacs A, Weinheimer C, Courtois M, Blumer KJ, Kelly DP, Muslin AJ. RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload. J Clin Invest 104: 567-576, 1999.
34. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58: 1072-1083, 1978.
35. Sanbe A, Gulick J, Hanks MC, Liang Q, Osinska H, Robbins J. Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter. Circ Res 92: 609-616, 2003.
36. Schmitt JP, Semsarian C, Arad M, Gannon J, Ahmad F, Duffy C, Lee RT, Seidman CE, Seidman JG. Consequences of pressure overload on sarcomere protein mutation-induced hypertrophic cardiomyopathy. Circulation 108: 1133-1138, 2003.
37. Stauffer BL, Konhilas JP, Luczak ED, Leinwand LA. Soy diet worsens heart disease in mice. J Clin Invest 116: 209-216, 2006.
38. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Reboldi G, Porcellati C. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97: 48-54, 1998.
39. Vikstrom KL, Bohlmeyer T, Factor SM, Leinwand LA. Hypertrophy, pathology, and molecular markers of cardiac pathogenesis. Circ Res 82: 773-778, 1998.
40. Vikstrom KL, Factor SM, Leinwand LA. Mice expressing mutant myosin heavy chains are a model for familial hypertrophic cardiomyopathy. Mol Med 2: 556-567, 1996.